ArticleCell and tissue banking2026
Seven-year experience (2018-2025) of a hospital-based cardiovascular tissue bank in Israel: operational insights and clinical impact.
Article in Cell and tissue banking, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryopreserved human heart valves and cardiovascular tissues (homografts) are essential for the surgical treatment of congenital and acquired valvular diseases, particularly in pediatric patients, where prosthetic options are limited. To address the clinical demand for high-quality grafts in Israel, Sheba Medical Center, the largest tertiary care hospital in Israel, established a Good Manufacturing Practice (GMP) compliant Cardiovascular Tissue Bank within the public health system. This report presents an overview of the bank's operation within the Israeli public health system over seven years, covering donor selection criteria, tissue processing procedures, microbiological safety measures, cryopreservation and distribution, as well as protocol optimization and validation. Between 2018 and early 2025, the tissue bank successfully transitioned from basic sterile techniques to full GMP-grade cleanroom operations, implementing validated protocols for decontamination, packaging, and cryopreservation. During this period, 142 donor hearts were processed, yielding 390 cardiovascular tissues, of which 338 were approved for clinical use and distributed to cardiac surgery centers across Israel. This paper provides a comprehensive operational overview of the Sheba Cardiovascular Tissue Bank from 2018 to 2025, describing protocol refinement, tissue procurement, processing, preservation, regulatory compliance, quality control, and distribution. By combining clinical collaboration, rigorous quality control, and GMP-based infrastructure, the bank plays a pivotal role in ensuring the availability of high-quality cryopreserved homografts for Israeli patients, especially pediatric cases with complex congenital heart disease, and provides a sustainable model for hospital-based cardiovascular tissue banking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.